Nektar Therapeutics (NASDAQ: NKTR) is a biopharmaceutical company focused on developing innovative medicines in areas of high unmet medical need. The company is known for its research in autoimmune diseases, oncology, and pain management. NKTR faces competition from other pharmaceutical companies that are also developing treatments for similar conditions.
On December 16, 2025, H.C. Wainwright set a price target of $135 for NKTR, while the stock was priced at $51.17. This suggests a potential price increase of approximately 164%. However, the stock is currently priced at $49.21, reflecting a decrease of 7.67% with a drop of $4.09. The stock has fluctuated between a low of $45.25 and a high of $52.29 during the trading day.
Nektar recently announced the topline results from its Phase 2b REZOLVE-AA trial. This trial evaluated the investigational drug rezpegaldesleukin for treating severe-to-very-severe alopecia areata, an autoimmune condition causing hair loss. The trial involved 92 patients over a 36-week period, focusing on the mean percentage reduction in the Severity of Alopecia Tool (SALT) score at Week 36.
Both dosage arms of rezpegaldesleukin showed more than double the reduction in SALT score compared to the placebo. Although the trial initially missed its primary endpoint, it achieved statistical significance after excluding certain patients. This development could impact NKTR's stock performance and investor sentiment.
NKTR has a market capitalization of approximately $1 billion, with a trading volume of 4,275,313 shares. Over the past year, the stock has seen a high of $66.92 and a low of $6.45. As NKTR continues its research and development efforts, the company's stock performance will be closely watched by investors and analysts.
